About Mitochondrial import receptor subunit TOM40 homolog
Mitochondrial import receptor subunit TOM40 homolog (TOMM40) is a protein
from Homo sapiens identified by UniProt accession
O96008, 361 residues long.
MolForge cross-references it against 0 known binders and
265 disease associations.
Target properties
| Protein name | Mitochondrial import receptor subunit TOM40 homolog |
| UniProt accession | O96008 |
| Gene | TOMM40 |
| Organism | Homo sapiens |
| Length | 361 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (265)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.36
- Alzheimer disease · score 0.34
- total cholesterol measurement · score 0.34
- low density lipoprotein cholesterol measurement · score 0.33
- family history of Alzheimer’s disease · score 0.33
- body mass index · score 0.32
- high density lipoprotein cholesterol measurement · score 0.32
- triglyceride measurement · score 0.31
- body fat percentage · score 0.30
- waist-hip ratio · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O96008-F1 | alphafold | PREDICTED | 78.36 | — |
Amino-acid sequence (361 residues)
MGNVLAASSP PAGPPPPPAP ALVGLPPPPP SPPGFTLPPL GGSLGAGTST SRSSERTPGA ATASASGAAE DGACGCLPNP GTFEECHRKC KELFPIQMEG VKLTVNKGLS NHFQVNHTVA LSTIGESNYH FGVTYVGTKQ LSPTEAFPVL VGDMDNSGSL NAQVIHQLGP GLRSKMAIQT QQSKFVNWQV DGEYRGSDFT AAVTLGNPDV LVGSGILVAH YLQSITPCLA LGGELVYHRR PGEEGTVMSL AGKYTLNNWL ATVTLGQAGM HATYYHKASD QLQVGVEFEA STRMQDTSVS FGYQLDLPKA NLLFKGSVDS NWIVGATLEK KLPPLPLTLA LGAFLNHRKN KFQCGFGLTI G
Explore Mitochondrial import receptor subunit TOM40 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets